The commission shall grant temporary non-preferred status to new drugs that are available but have not yet been reviewed by the board and establish criteria for authorizing drugs with temporary non-preferred status.

Transferred, redesignated and amended by Acts 2025, 89th Leg., R.S., Ch. 204 (H.B. 1620), Sec. 8.049(c), eff. September 1, 2025.

Added by Acts 2023, 88th Leg., R.S., Ch. 739 (H.B. 3286), Sec. 3, eff. September 1, 2023.